

Copyrights © 2014 Business Standard Ltd. All rights reserved.

Wed, 11 Jul-18; Business Standard - Pune; Size : 47 sq.cm.;
Circulation:5667; Page : 2

Pharma sector likely to post moderate growth

The domestic pharmaceutical sector is likely to post a moderate, single-digit revenue growth in the current fiscal year, on slowing US market growth, increased competition and regulatory overhang, a report said.

Consolidation of supply chain in the US market resulting in pricing pressures along with sustained investments in research and development will also have an impact on profitability of Indian pharmaceutical firms, Icria said.

“The growth trajectory for Indian industry may be moderate, in single digit, on slowing growth from the US given the relatively moderate proportion of large-size drugs going off patent, competition leading to price erosion in low double digit,” it said. **PTI**